Is Arcus Biosciences Inc (RCUS) overvalued? · rev $258.0M
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
This page asks whether Arcus Biosciences Inc (RCUS) looks expensive on cached numbers — not a short thesis.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
RCUS currently screens at market cap $885.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RCUS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RCUS stock page for the full model, not this heading.
Not investment advice.